title: Considerations for human papillomavirus (HPV) vaccination of mid-adult women in the United States.
abstract: In the United States, human papillomavirus (HPV) vaccination is recommended for 11 or 12 year old girls, with catch-up vaccination through age 26 years. Data are available for women over the age of 26 years on immunogenicity for both quadrivalent and bivalent HPV vaccines and on efficacy for the quadrivalent HPV vaccine. If HPV vaccines are licensed for use in women over 26 years of age (mid-adult women), recommendations for this age group will need to be considered. This review summarizes vaccine efficacy and immunogenicity data in mid-adult women, and addresses epidemiologic data related to key questions for consideration of vaccine recommendations for women over age 26 years.
authors.affiliation: Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
authors.forename: Linda Ahdieh
authors.initials: LA
authors.lastname: Grant
authors.forename: Eileen F
authors.initials: EF
authors.lastname: Dunne
authors.forename: Harrell
authors.initials: H
authors.lastname: Chesson
authors.forename: Lauri E
authors.initials: LE
authors.lastname: Markowitz
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D014481:United States / Q000453:epidemiology; D014611:Vaccination
chemical_list: D053918:Papillomavirus Vaccines